Search Videos by Topic or Participant
Browse by Series:

When to Initiate Treatment for ITP

Panelists: Howard A. Liebman, MD, USC; Keith McCrae, MD, Cleveland Clinic; Ivy Altomare, MD, Duke 
Published: Tuesday, Mar 03, 2015
For High-Definition, Click
The goal of idiopathic thrombocytopenic purpura (ITP) treatment, explains Ivy Altomare, MD, is to treat active bleeding or reduce the risk of bleeding. Determining when to treat a patient with ITP depends on several factors, says Howard A. Liebman, MD, including patient preference and clinical manifestations.

The majority opinion is that patients should consider treatment, if they are not bleeding, only when platelet counts are less than 30,000. Keith McCrae, MD, states that a sedentary person’s platelet count can go quite low, perhaps even below 20,000, before therapy is required. Individuals with a platelet count around 30,000 do not usually have clinically significant bleeding that would put them at risk.

It is also important to consider patient characteristics, such as age and comorbidities, Altomare notes. Older individuals with coronary artery disease taking antiplatelet therapy may be at higher risk of bleeding.
Slider Left
Slider Right
For High-Definition, Click
The goal of idiopathic thrombocytopenic purpura (ITP) treatment, explains Ivy Altomare, MD, is to treat active bleeding or reduce the risk of bleeding. Determining when to treat a patient with ITP depends on several factors, says Howard A. Liebman, MD, including patient preference and clinical manifestations.

The majority opinion is that patients should consider treatment, if they are not bleeding, only when platelet counts are less than 30,000. Keith McCrae, MD, states that a sedentary person’s platelet count can go quite low, perhaps even below 20,000, before therapy is required. Individuals with a platelet count around 30,000 do not usually have clinically significant bleeding that would put them at risk.

It is also important to consider patient characteristics, such as age and comorbidities, Altomare notes. Older individuals with coronary artery disease taking antiplatelet therapy may be at higher risk of bleeding.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x